Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1986 4
1987 3
1988 35
1989 33
1990 53
1991 40
1992 46
1993 71
1994 74
1995 61
1996 80
1997 71
1998 67
1999 99
2000 96
2001 90
2002 155
2003 106
2004 140
2005 152
2006 169
2007 169
2008 191
2009 208
2010 249
2011 252
2012 240
2013 284
2014 317
2015 346
2016 376
2017 372
2018 333
2019 360
2020 386
2021 386
2022 356
2023 325
2024 80

Text availability

Article attribute

Article type

Publication date

Search Results

6,022 results

Results by year

Filters applied: . Clear all
Page 1
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. Brown JR, et al. N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13. N Engl J Med. 2023. PMID: 36511784 Clinical Trial.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Seymour JF, et al. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Siddiqi T, Maloney DG, Kenderian SS, Brander DM, Dorritie K, Soumerai J, Riedell PA, Shah NN, Nath R, Fakhri B, Stephens DM, Ma S, Feldman T, Solomon SR, Schuster SJ, Perna SK, Tuazon SA, Ou SS, Papp E, Peiser L, Chen Y, Wierda WG. Siddiqi T, et al. Lancet. 2023 Aug 19;402(10402):641-654. doi: 10.1016/S0140-6736(23)01052-8. Epub 2023 Jun 6. Lancet. 2023. PMID: 37295445 Clinical Trial.
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.
Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Šimkovič M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Österborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W. Hillmen P, et al. J Clin Oncol. 2023 Feb 10;41(5):1035-1045. doi: 10.1200/JCO.22.00510. Epub 2022 Nov 17. J Clin Oncol. 2023. PMID: 36395435 Free PMC article. Clinical Trial.
Richter's Transformation.
Sigmund AM, Kittai AS. Sigmund AM, et al. Curr Oncol Rep. 2022 Aug;24(8):1081-1090. doi: 10.1007/s11912-022-01274-4. Epub 2022 Apr 6. Curr Oncol Rep. 2022. PMID: 35384590 Review.
Frontline Therapy in Chronic Lymphocytic Leukemia.
Arguello-Tomas M, Albiol N, Moreno C. Arguello-Tomas M, et al. Acta Haematol. 2024;147(1):47-59. doi: 10.1159/000534730. Epub 2023 Oct 27. Acta Haematol. 2024. PMID: 37899041 Review.
Idelalisib.
Zirlik K, Veelken H. Zirlik K, et al. Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12. Recent Results Cancer Res. 2018. PMID: 30069634 Review.
6,022 results